leadf
logo-loader
viewIQ-AI Limited

IQ-AI’s Imaging Biometrics has software platform installed at Barrow Neurological Institute

The investment firm said IB’s Rad Tech software would be used to help assess treatment response options for patients with brain tumours

Brain scan
Mapping from the software has been shown to help clinicians distinguish between tumour and non-tumour tissue

IQ-AI Limited’s (LON:IQAI) subsidiary Imaging Biometrics has had its new IB Rad Tech software platform installed at the Barrow Neurological Institute in St. Joseph's Hospital and Medical Center in Arizona.

The investment firm said IB’s Rad Tech software would be used to help assess treatment response options for patients with brain tumours and was chosen for its “ability to efficiently generate quantitative maps of enhancing regions of tumour (Delta T1) and fractional tumour burden (FTB)”.

READ: IQ-AI’s Imaging Biometrics appoints South Korean distributor as it receives regulatory certification

These perfusion-derived FTB maps have been shown to help clinicians in distinguishing between tumour and non-tumour tissue.

David Smith, chief executive of Imaging Biometrics, said: "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumour patients”.

“Removing the variability of the manually-placed [regions of interest] is a more repeatable and faster method to do inter- and intra-study comparisons for multi-centre clinical trials as well."

The installation follows IB’s appointment of a South Korean distributor for its diagnostic imaging products in November after receiving ISO regulatory certification for its medical devices and quality management systems.

Quick facts: IQ-AI Limited

Price: 12.8 GBX

LSE:IQAI
Market: LSE
Market Cap: £20.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise...

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before...

on 15/7/20

2 min read